“`html
Study Title: Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy
Purpose
- Investigate changes in immune tumor microenvironment (iTME) in ovarian cancer patients undergoing neoadjuvant chemotherapy (NACT)
- Correlate changes in immune cell subsets and coregulators with clinical outcomes
Experimental Design
- Used multiplexed immune profiling and cell clustering analysis on paired ovarian cancer samples
- Patients were enrolled in the CHIVA trial (NCT01583322)
Results
- Higher CD8+ T cells and HLA-1+ enriched tumors at diagnosis were associated with better outcomes
- Increased CD8+/Foxp3+ ratio post-NACT predicted improved immune surveillance and better outcomes
- Clustering analysis identified different immune cell subsets within ovarian cancer, which could guide personalized approaches
- Targeting immune checkpoints such as TIM-3, LAG-3, and IDO-1 may be more effective in harnessing anti-tumor immunity in this type of cancer
Conclusions
- Various immune tumor microenvironments exist during tumor evolution, and the impact of NACT on iTME is diverse
- Clustering analysis of patients’ immune cell subsets within ovarian cancer may inform personalized treatment strategies
- Targeting different immune checkpoints like TIM-3, LAG-3, and IDO-1, which are more prevalent than PD-L1, could be more effective in treating anti-PD-L1 resistant ovarian cancer
“`
